These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 19010832)

  • 1. Microtubule active agents: beyond the taxane frontier.
    Morris PG; Fornier MN
    Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.
    Morris PG; Fornier MN
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on tubulin-binding agents.
    Attard G; Greystoke A; Kaye S; De Bono J
    Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing the pore drug binding site of microtubules with fluorescent taxanes: evidence of two binding poses.
    Barasoain I; García-Carril AM; Matesanz R; Maccari G; Trigili C; Mori M; Shi JZ; Fang WS; Andreu JM; Botta M; Díaz JF
    Chem Biol; 2010 Mar; 17(3):243-53. PubMed ID: 20338516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cevipabulin (TTI-237): preclinical and clinical results for a novel antimicrotubule agent.
    Ayral-Kaloustian S; Zhang N; Beyer C
    Methods Find Exp Clin Pharmacol; 2009 Sep; 31(7):443-7. PubMed ID: 19907719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epothilones: mechanism of action and biologic activity.
    Goodin S; Kane MP; Rubin EH
    J Clin Oncol; 2004 May; 22(10):2015-25. PubMed ID: 15143095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel agents that target tublin and related elements.
    Rowinsky EK; Calvo E
    Semin Oncol; 2006 Aug; 33(4):421-35. PubMed ID: 16890797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current perspectives of epothilones in breast cancer.
    Cardoso F; de Azambuja E; Lago LD
    Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule alterations and resistance to tubulin-binding agents (review).
    Drukman S; Kavallaris M
    Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubulin: an example of targeted chemotherapy.
    Seligmann J; Twelves C
    Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
    Jordan MA; Horwitz SB; Lobert S; Correia JJ
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
    Fojo T; Menefee M
    Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epothilones: how pharmacology relates to clinical utility.
    Michaud LB
    Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microtubule stabilising agents for cancer chemotherapy.
    Zhao Y; Fang WS; Pors K
    Expert Opin Ther Pat; 2009 May; 19(5):607-22. PubMed ID: 19441937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.